Morphine blood-brain barrier transport is influenced by probenecid co-administration

Pharmaceutical Research

Volumn 20, Issue 4, 2003, Pages 618-623

  Tunblad, Karin ^a   Jonsson, E Niclas ^a   Hammarlund Udenaes, Margareta ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Blood brain barrier; Microdialysis; Modeling; Morphine; Probenecid sensitive transporters

Indexed keywords

MORPHINE; PROBENECID;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CALIBRATION; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INFUSION; DRUG TRANSPORT; JUGULAR VEIN; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; STEADY STATE;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BRAIN; DRUG INTERACTIONS; MALE; MICRODIALYSIS; MORPHINE; PROBENECID; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0037392850     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023250900462     Document Type: Article

References (30)

1. M. Hammarlund-Udenaes, L. K. Paalzow, and E. C. de Lange. Drug equilibration across the blood-brain barrier - pharmacokinetic considerations based on the microdialysis method. Pharm. Res. 14:128-134 (1997).
2. R. Xie, M. Hammarlund-Udenaes, A. G. de Boer, and E. C. de Lange. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br. J. Pharmacol. 128:563-568 (1999).
3. S. P. Letrent, G. M. Pollack, K. R. Brouwer, and K. L. Brouwer. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab. Dispos. 27:827-834 (1999).
4. R. Xie, M. R. Bouw, and M. Hammarlund-Udenaes. Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. Br. J. Pharmacol. 131:1784-1792 (2000).
5. R. A. Morin and W. H. Lyness. Potentiation of morphine analgesia after pretreatment with probenecid or sulfinpyrazone. Pharmacol. Biochem. Behav. 18:885-889 (1983).
6. Z. Hollo, L. Homolya, T. Hegedus, and B. Sarkadi. Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett. 383:99-104 (1996).
7. N. H. Hendrikse, E. J. Franssen, W. T. van der Graaf, C. Meijer, D. A. Piers, W. Vaalburg, and E. G. de Vries. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br. J. Cancer 77:353-358 (1998).
8. P. Borst, R. Evers, M. Kool, and J. Wijnholds. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:1295-1302 (2000).
9. Y. Zhang, H. Han, W. F. Elmquist, and D. W. Miller. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. 876:148-153 (2000).
10. D. Sugiyama, H. Kusuhara, Y. Shitara, T. Abe, P. J. Meier, T. Sekine, H. Endou, H. Suzuki, and Y. Sugiyama. Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J. Pharmacol. Exp. Ther. 298:316-322 (2001).
11. C. K. Kuo, N. Hanioka, Y. Hoshikawa, K. Oguri, and H. Yoshimura. Species difference of site-selective glucuronidation of morphine. J. Pharmacobiodyn. 14:187-193 (1991).
12. J. T. Van Crugten, B. C. Sallustio, R. L. Nation, and A. A. Somogyi. Renal tubular transport of morphine, morphine-6-glucuronide, and morphine-3-glucuronide in the isolated perfused rat kidney. Drug Metab. Dispos. 19:1087-1092 (1991).
13. M. R. Bouw and M. Hammarlund-Udenaes. Methodological aspects of the use of a calibrator in in vivo microdialysis-further development of the retrodialysis method. Pharm. Res. 15:1673-1679 (1998).
14. S. L. Shafer, L. C. Siegel, J. E. Cooke, and J. C. Scott. Testing computer-controlled infusion pumps by simulation. Anesthesiology 68:261-266 (1988).
15. M. Ekblom, M. Hammarlund-Udenaes, and L. Paalzow. Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats. J. Pharmacol. Exp. Ther. 266:244-252 (1993).
16. S. P. Joel, R. J. Osborne, and M. L. Slevin. An improved method for the simultaneous determination of morphine and its principal glucuronide metabolites. J. Chromatogr. 430:394-399 1988).
17. S. L. Beal and L. S. Sheiner. NONMEM User's Guide. NONMEM Project Group, University of California at San Fransisco, San Fransisco, California, 1992.
18. E. N. Jonsson and M. O. Karlsson. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64 (1999).
19. Y. Wang and D. F. Welty. The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. Pharm. Res. 13:398-403 (1996).
20. G. Skopp, L. Potsch, B. Ganssmann, R. Aderjan, and R. Mattern. A preliminary study on the distribution of morphine and its glucuronides in the subcompartments of blood. J. Anal. Toxicol. 22:261-264 (1998).
21. U. Bickel, O. P. Schumacher, Y. S. Kang, and K. Voigt. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J. Pharmacol. Exp. Ther. 278:107-113 (1996).
22. C. J. Matheny, M. W. Lamb, K. R. Brouwer, and G. M. Pollack. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21:778-796 (2001).
23. M. R. Bouw, M. Gardmark, and M. Hammarlund-Udenaes. Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats - a microdialysis study. Pharm. Res. 17:1220-1227 (2000).
24. I. Szentistvanyi, C. S. Patlak, R. A. Ellis, and H. F. Cserr. Drainage of interstitial fluid from different regions of rat brain. Am. J. Physiol. 246:F835-F844 (1984).
25. G. A. Rosenberg, W. T. Kyner, and E. Estrada. Bulk flow of brain interstitial fluid under normal and hyperosmolar conditions. Am. J. Physiol. 238:F42-F49 (1980).
26. R. A. Upton, R. L. Williams, J. N. Buskin, and R. M. Jones. Effects of probenecid on ketoprofen kinetics. Clin. Pharmacol. Ther. 31:705-712 (1982).
27. P. C. Smith, P. N. Langendijk, J. A. Bosso, and L. Z. Benet. Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. Clin. Pharmacol. Ther. 38:121-127 (1985).
28. J. F. Ghersi-Egea, B. Leninger-Muller, G. Suleman, G. Siest, and A. Minn. Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs. J. Neurochem. 62:1089-1096 (1994).
29. P. M. Bungay, P. F. Morrison, and R. L. Dedrick. Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro. Life Sci. 46:105-119 (1990).
30. H. Sun, P. M. Bungay, and W. F. Elmquist. Effect of capillary efflux transport inhibition on the determination of probe recovery during in vivo microdialysis in the brain. J. Pharmacol. Exp. Ther. 297:991-1000 (2001).